Prescription drug boom fuels CVS growth in run-up to Aetna merger

Published



Increasing prescription drug sales fueled third-quarter profit growth at CVS Health as executives worked to complete a $69 billion merger with Aetna.

Revenue at the Woonsocket, R.I.-based pharmacy chain grew 2.4 percent to $47.3 billion, supported by a nearly 10 percent increase in same-store prescription treatment sales. Profit rose 8.2 percent to $1.4 billion, or $1.36 per share, higher than analyst’s expected.

Full midterm coverage.Deeper analysis.

Get unlimited access to Washington Examiner's reporting, expert analysis, and coverage of the midterm elections.

Get Unlimited Access

Cancel anytime.